Asia · Markets & Finance · The Financial Express

US Pharma Tariff Relief: Which Indian pharma stocks benefit and which face trade risk?

Published by The Financial Express · India 11 h ago

US pharma tariff relief has different implications for Indian drugmakers, with generic, specialty, injectable and CDMO businesses facing distinct risks and opportunities.

Read the full article on The Financial Express Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.financialexpress.com)

Also worth reading

Tech in Asia

Could Northern Metropolis draw educational leasing from Hong Kong’s Grade A office sector?

Business Standard

TCS to buy US retailer Best Buy's India GCC, develop an AI-native centre

Moneycontrol

US Pharma Tariff Relief: Which Indian pharma stocks benefit and which face trade risk?

Share

Also worth reading

Anthropic targets mid-November IPO after delay

India-Canada trade target jumps to $70 billion

H1 digest: New capex proposals rise, but momentum plunges in September quarter

Could Northern Metropolis draw educational leasing from Hong Kong’s Grade A office sector?

TCS to buy US retailer Best Buy's India GCC, develop an AI-native centre

Accenture flags lower pricing in Q4, sees intense competition ahead